Tumor microenvironment: what have we learned studying the immune response in this puzzling battlefield?
Recent developments hallmark the progress in the understanding of tumor immunology and related therapeutic strategies. The administration of interleukin-2 (IL-2) to patients with cancer has shown that immune manipulation can mediate the regression of established cancers. The identification of the genes encoding cancer antigens and the development of means for effectively immunizing against these antigens has opened new avenues for the development of active immunization of patients with cancer. However, an efficient immune response against tumor comprises an intricate molecular network still poorly understood. Only when the code governing immune responsiveness of cancer will be deciphered, new therapeutic strategies could be designed to fit biologically defined mechanisms of immune rejection of cancer. In this review, we propose that the mechanisms regulating tumor rejection in response to vaccination will be more efficiently identified by following the evolution of treatment induced events within the tumor microenvironment taking advantage of recently developed technological tools. As a model, we will discuss the observed immune response to tumor antigen -specific immunization and its relationship with the systemic administration of IL-2.
Mocellin
Simone
S
Immunnogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA.
Panelli
Monica
M
Wang
Ena
E
Rossi
Carlo Riccardo
CR
Marincola
Francesco M
FM
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage; D019496:Cancer Vaccines / Q000276:immunology*; D006801:Humans; D007376:Interleukin-2 / Q000008:administration & dosage; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology*
D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D007376:Interleukin-2